Immune checkpoint inhibitors (ICIs) have emerged as a promising approach to treat various types of cancers. However, the response to ICI-based cancer immunotherapy can vary significantly among patients, highlighting the need for predictive biomarkers that can help identify individuals who are likely to benefit from these treatments.
Creative Biolabs provides the analysis service of predictive biomarkers for ICI-based cancer immunotherapy, focusing on four key aspects: tumor cells-related biomarkers analysis, tumor microenvironment (TME) phenotype biomarkers analysis, liquid biopsy biomarkers analysis, and host-related markers analysis.
Fig.1 Overview of predictive biomarkers for ICI efficacy. (Bai, et al., 2020)
Understanding the characteristics of tumor cells is crucial for predicting the response to ICI-based cancer immunotherapy. We provide several tumor cells-related biomarkers analysis for their predictive potential, including:
One of the key TME phenotype biomarkers is the presence of tumor-infiltrating lymphocytes (TILs). TILs, particularly CD8+ T cells, have been associated with improved response to ICIs in various cancer types.
Additionally, the immunosuppressive TME, characterized by the presence of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), has been associated with resistance to ICIs. Therefore, analyzing the composition and functional status of TILs, Tregs, and MDSCs can help predict the response to ICI-based cancer immunotherapy.
Liquid biopsy has emerged as a non-invasive and convenient method for biomarker analysis in cancer patients. By analyzing various components, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, liquid biopsy can provide valuable information about tumor dynamics and treatment response. Typically, we provide the following biomarkers analysis:
Apart from tumor-specific biomarkers, host-related markers play a crucial role in predicting the response to ICI-based cancer immunotherapy. The genetic makeup and immune profile of patients can influence their ability to mount an effective anti-tumor immune response. We provide biomarkers analysis for the following host-related markers:
Additionally, considering that the type of ICIs is more correlated with treatment, Creative Biolabs also provides predictive markers analysis for different ICI types, including but not limited to:
By analyzing these biomarkers, researchers can make informed decisions and personalize treatment strategies, ultimately improving patient outcomes.
Creative Biolabs is committed to advancing the field of predictive biomarker analysis and providing innovative solutions to enhance the efficacy of ICI-based cancer immunotherapy. Please feel free to contact us for more about our Treg related services.
For Research Use Only | Not For Clinical Use
Download our brochure